Study of an investigational medicine for moderate to severe psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests an investigational drug (DDY391) in people with moderate to severe psoriatic arthritis. The goal is to see how well it works and if it is safe, which might help reduce joint pain and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with psoriatic arthritis.
- Your psoriatic arthritis is moderate to severe.
- You have not used certain arthritis or psoriasis medications recently, or you have not taken specific newer oral medicines (JAK inhibitors) before.
- You do not have other inflammatory conditions like rheumatoid arthritis, lupus, or fibromyalgia.
- You have not had cancer in the last 5 years (except for treated skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called JNJ-88545223 to see if it can reduce joint pain, swelling, and skin plaques in people with active psoriatic arthritis. It may help if you have both joint symptoms and psoriasis.
This trial tests an experimental drug called FT2109 for people with psoriatic arthritis, a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if FT2109 can reduce symptoms and improve quality of life.
This trial tests adding a new oral medication (deucravacitinib) to your current anti-TNF therapy to see if it helps better control psoriatic arthritis or psoriasis that hasn't improved enough. It may be an option if you still have active symptoms despite being on a stable anti-TNF treatment for at least 6 months.
This trial tests an oral medication, D-2570, for people with active psoriatic arthritis. It aims to see if the drug can reduce joint pain and swelling.
This trial tests an investigational drug for people with moderate-to-severe rheumatoid arthritis who haven't responded well to previous treatments. It aims to see if the drug can reduce joint pain and swelling.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
Hear when a new Moderate to Severe Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.